Enhanced Oral Bioavailability of Efavirenz by Solid Lipid Nanoparticles: In Vitro Drug Release and Pharmacokinetics Studies

Table 2

Formulations composition.

Formulation code	Type of formulation	Drug : lipid	Surfactant (%)
ES	Suspension (1% drug)
ESLN-0	SLN	1 : 3	0.5
ESLN-1	SLN	1 : 3	0.75
ESLN-2	SLN	1 : 3	1.0
ESLN-3	SLN	1 : 3	1.25